Dendritic cell-based immunotherapy for ovrian cancer patients.
Not Applicable
Completed
- Conditions
- Neoplasms
- Registration Number
- KCT0000831
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 10
Inclusion Criteria
Age: 20~69 years old
-Systemic condition: ECOG<3
-Pregressed disease patients
-Disease status : patients with metastatic ovarian cancer at diagnosis or relapsed after diagnosis
-Pt with proper kidney, liver and bone marrow functions
1) Hb 10.0g/dl, WBC 3,500/ul, PLT 100,000/ul
2) Serum Creatinin level < 1.25 times of normal healthy people
3) Serum SGOT/SGPT level < 3 times of normal healthy people
-Signed informed consent, volutarily
Exclusion Criteria
-Pts with active infection
-Defects on heart, liver, lung, brain and/or kidney function.
-Pregnant or women with possibility of pregnancy (positive with test.)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and Efficacy of DC vaccine treatment - Grade 0~4 toxicity, elimination of clinical tumor burden (CR/PR/PD/SD)
- Secondary Outcome Measures
Name Time Method Tumor antigen-specific immune monitoring from the peripheral blood -NK cell activity, lymphocyte proportion and function, cytokine secretion, and effector T cell induction.